Earnings call transcript: TransMedics Q1 2026 misses EPS forecast, stock stable

TransMedics reported Q1 2026 EPS of $0.30, missing the $0.62 consensus by 51.6%, while revenue of $173.9 million was roughly in line and up 21% year over year. Gross margin was 58%, down 331 bps y/y, and adjusted operating expenses rose 42% as the company continued heavy investment in CHOPS, OCS Kidney, and Europe expansion. Despite the miss, the stock rose 0.55% after hours to $97.61, and management reaffirmed full-year 2026 revenue guidance of $727 million-$757 million.

Analysis

The market is telling us the quarter matters less than the setup: TMDX is transitioning from a pure utilization story to a capital-intensity story, and that usually compresses multiple before it expands it. The near-term risk is not demand, but denominator risk — every incremental dollar into CHOPS, Europe, Gen 3.0, and kidney raises the bar for margin inflection, so the stock will trade on evidence of operating leverage rather than top-line growth alone. If management is right, the next re-rate is a function of proving that investment phase peaks in 2H26 while volume keeps compounding; if not, this becomes a classic “great story, messy model” name.

The bigger second-order effect is competitive positioning. By creating an internally controlled cold-storage standard, TMDX is trying to neutralize trial design noise and pull short-duration heart cases into its ecosystem, which should pressure smaller logistics vendors and any point-solution cooler suppliers that depend on physician inertia. That also broadens the addressable market beyond the high-acuity, long-haul cases that have driven the premium narrative, but it risks cannibalizing some mix if low-duration cases migrate to a lower-ASP pathway. The important nuance: the economics may still be superior if CHOPS increases attachment to the logistics network and keeps centers inside the TransMedics workflow.

The contrarian setup is that the miss is likely being misread as a demand issue when it is more plausibly a timing issue tied to strategic interference and internal investment. Consensus is probably underestimating how much of 2026 is already about proving clinical optionality, not maximizing current-quarter earnings; that means the stock can stay resilient even with margin pressure as long as case growth and enrollment progress remain intact. The real catalyst window is early Q3 into year-end, when CHOPS implementation and Part B/DENOVO enrollment either validate the platform expansion or expose that the commercial engine is more fragile than management implies.

Key Decisions for Investors

• Maintain a tactical long TMDX, but only via staged entry on weakness over the next 1-2 weeks; target a 10-15% upside move if CHOPS/IDE timing is confirmed, with a stop if commentary on enrollment slips into 2027.
• Sell near-dated upside calls against existing TMDX longs into pre-IDE volatility; the stock is likely to oscillate around execution milestones rather than trend cleanly until Q3, making covered calls attractive for income with limited opportunity cost.
• Pair trade: long TMDX / short a basket of small-cap transplant/logistics competitors or cooler-adjacent medtech names, betting that the new internal control arm and logistics integration consolidate share over 3-6 months.
• If you want asymmetric exposure, buy TMDX call spreads dated Jan-2027; the trade monetizes a successful transition to a kidney/Europe/CHOPS platform story while capping premium burn if margins stay under pressure.
• Avoid adding on earnings strength alone; wait for either IDE approval or evidence that SG&A/R&D growth is decelerating, because the stock is likely to re-rate on margin trajectory, not headline revenue growth.